Welcome to the OMA Blog

Growing up in rural West Virginia, Mollie Cecil, MD, DABOM, FAAFP, experienced firsthand both the challenges and the strengths of small communities.

For Alina Elperin, MD, DABOM, medicine has always been about more than diagnosing and treating disease. As an internal medicine physician and Diplomate of the American Board of Obesity Medicine since 2016, her passion lies within prevention.

For the past decade, Al Robaina, MD, DABOM, has been helping patients as a board-certified internal medicine physician, helping patients with a variety of conditions such as hypertension, diabetes, and lipid disorders. But as he looked deeper at the root causes of many of those diseases, he realized there was one disease that seemed to be linked to them all: obesity.

For Aradhna Saraswat, MD, DABOM, obesity medicine is about more than helping patients reach their health goals; it’s about creating a space where they can be vulnerable, heard and understood.

For more than 40 years, Deborah Juda, RD, LDN, has dedicated her career to helping people better understand nutrition, weight management and obesity care.

For years, Alicia Shelly, MD, DABOM, built meaningful relationships with patients through primary care, helping them navigate life’s challenges and celebrating their successes along the way. Today, as a board-certified internal medicine physician and a Diplomate of the American Board of Obesity Medicine, Dr. Shelly practices obesity medicine full-time, helping patients through comprehensive and compassionate obesity care.

Medicare coverage of GLP-1s for weight loss indications will occur under the Medicare GLP-1 Bridge Model, rather than the BALANCE Model, through December 31, 2027. Eligible Medicare beneficiaries will continue to have access to covered GLP-1 medications nationwide with a fixed $50 copay through the extended Bridge Model. While the Bridge Model was originally scheduled to end December 31, 2026 – to be replaced by BALANCE on January 1, 2027 – CMS extended the Bridge Model to allow for ongoing coverage of GLP-1 medications given the delay of the BALANCE model. The extension of the Bridge Model will enable eligible Part D beneficiaries across the country to access covered GLP-1 medications through December 2027, regardless of their Part D plan sponsors’ participation decisions. CMS’ announced changes to Medicare coverage of GLP-1 medications are not expected to affect Medicaid coverage of the medications under the BALANCE model.

An international steering group conducted a rigorous global consensus process for renaming polycystic ovary syndrome, leading to a consensus regarding the terminology change

Discover the most effective weight loss medications approved by the FDA. Comprehensive guide on safety, dosage, and efficacy for 2025.